Tyrx gets FDA OK for advanced antibacterial pacemaker envelope

07/10/2013 | Xconomy

Tyrx has gained FDA clearance for a second-generation version of its AigisRx Antibacterial Envelope, designed to protect patients receiving pacemakers and other implantable heart devices from infection. The drug-device combination discharges two antibiotics within seven to 10 days and completely dissolves in the body in about 90 days, CEO Bob White said.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park